Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 856, Issue 1-2, 2007, Pages 190-197

  Liu, Dongyang ^a   Hu, Pei ^a   Matsushima, Nobuko ^b   Li, Xiaoming ^a   Li, Li ^a   Jiang, Ji ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Antihypertensive; Olmesartan; Plasma; Urine

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PHASE SEPARATION; PLASMA (HUMAN);

ANTIHYPERTENSIVE; OLMESARTAN; TANDEM MASS SPECTROMETRY; URINE;

DRUG PRODUCTS;

OLMESARTAN;

ARTICLE; CHINESE; CONTROLLED STUDY; ELUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; URINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMIDAZOLES; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TETRAZOLES;

EID: 34548134811     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.05.049     Document Type: Article

References (8)

1. Koga K., Yamagishi S., Takeuchi M., Inagaki Y., Amano S., Okamoto T., Saga T., Makita Z., and Yoshizuka M. Mol. Med. 8 (2002) 591
2. Schwocho L.R., and Masonson H.N. J. Clin. Pharmacol. 41 (2001) 515
3. Kobayashi N., Fujimori I., Watanabe M., and Ikeda T. Anal. Biochem. 287 (2000) 272
4. Nakamura H., Inoue T., Arakawa N., Shimizu Y., Yoshigae Y., Fujimori I., Shimakawa E., Toyoshi T., and Yokoyama T. Eur. J. Pharmacol. 512 (2005) 239
5. Laeis P., Puchler K., and Kirch W. J. Hypertens. 19 (2001) S21
6. US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical Method validation, US Department of Health and Human Services: Rockville, MD, 2001. Website: http://www.fda.gov/cder/guidance/index.htm.
7. State food and drug administration, The Guidance of bioavailability and bioequivalence study technique for chemistry drug in human (No. [H]GCL2-1) 2005. Website: http://www.sda.gov.cn/gsz05106/08.pdf.
8. Taylor P.J. Clin. Chem. 38 (2005) 328